Skip to main content
. Author manuscript; available in PMC: 2023 Aug 2.
Published in final edited form as: Vaccine. 2020 Oct 27;38(50):8032–8039. doi: 10.1016/j.vaccine.2020.10.019

Table 3.

Base case estimates of health impact: Estimated number of HPV-associated cancers averted by vaccination over 100-year vaccination program

Subgroup examined Comparison strategy (vaccination of females aged 12–26 years, and males aged 12–21 years) Mid-adult vaccination strategy (vaccination of females and males aged 12–45 years) Incremental benefit of mid-adult vaccination
Cancers averted in females 957,776 969,345 11,568
Cancers averted in males 489,776 499,142 9,366
Total cancers averted 1,447,552 1,468,486 20,934

The first column of results shows the number of cancers averted by the comparison scenario of routine 9vHPV vaccination of 12-year-old females and males with catch-up vaccination through age 26 years for females and 21 years for males (versus no vaccination). The second column of results shows the number of cancers averted when adding mid-adults to the vaccination program (routine 9vHPV vaccination of 12-year-old females and males with catch-up vaccination through age 45 years for females and males versus no vaccination). The third column of results shows the incremental benefits of mid-adult vaccination (vaccination through age 45 years) and was calculated as the number of cancers averted by the mid-adult vaccination scenario minus the number of cancers averted by the comparison scenario. These outcomes were not discounted.